Congressional Oversight of Medicare Program Intensifies: A Look at the Factors Surrounding the Scrutiny and Nephrology's Response

Singh, 2006, Correction of anemia with epoetin alfa in chronic kidney disease, N Engl J Med, 355, 2085, 10.1056/NEJMoa065485 Drueke, 2006, Normalization of hemoglobin level in patients with chronic kidney disease and anemia, N Engl J Med, 355, 2071, 10.1056/NEJMoa062276 Thamer, 2007, Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis, JAMA, 297, 1667, 10.1001/jama.297.15.1667 Thomas, 2006, Hearing on Patient Safety and Quality Issues in End Stage Renal Disease Treatment, Means CoWa; U.S. House of Representatives, 109, 87 Walker DM: Testimony Before the Committee on Ways and Means, House of Representatives. End-Stage Renal Disease: Medicare Payments for All ESRD Services, Including Injectable Drugs, Should Be Bundled, Office USGA, 2006 FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs). Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01582.html. Accessed August 20, 2007 Pollack A: Anemia drugs under review by Congress. New York Times, Business section, March 22, 2007 Pollack A: F.D.A. warning is issued on anemia drugs' overuse. New York Times, Washington section, March 10, 2007 U.S. to review anemia drugs for safety. New York Times, Business section, March 15, 2007 1999 2001 Physician Quality Reporting Initiative. Available at: http://www.cms.hhs.gov/pqri/. Accessed August 8, 2007 Physician Quality Reporting Initiative-Measures/Codes. Available at: http://www.cms.hhs.gov/PQRI/15_MeasuresCodes.asp#TopOfPage. Accessed August 8, 2007 Participation Tools: Medicare Physician Quality Reporting Initiative (PQRI). Available at: http://www.ama-assn.org/ama/pub/category/17432.html. Accessed August 10, 2007 Tax Relief and Health Care Act of 2006, Pub. L. no 109-432, 2006 Centers for Medicare and Medicaid Services (CMS), Pub 100-04 Medicare Claims Processing, Transmittal 751, Change Request 4135; National Monitoring Policy for EPO and Aranesp for End Stage Renal Disease (ESRD) Patients Treated in Renal Dialysis Facilities; November 10, 2005